PortfoliosLab logoPortfoliosLab logo
RGLD vs. RIGL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RGLD vs. RIGL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Royal Gold, Inc. (RGLD) and Rigel Pharmaceuticals, Inc. (RIGL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RGLD achieves a -10.20% return, which is significantly higher than RIGL's -14.06% return. Over the past 10 years, RGLD has outperformed RIGL with an annualized return of 10.07%, while RIGL has yielded a comparatively lower 3.86% annualized return.


RGLD

1D
-2.31%
1M
0.02%
6M
-24.35%
YTD
-10.20%
1Y
32.12%
3Y*
21.00%
5Y*
11.59%
10Y*
10.07%
ALL TIME*
16.03%

RIGL

1D
-3.28%
1M
-3.87%
6M
5.59%
YTD
-14.06%
1Y
74.79%
3Y*
40.40%
5Y*
-1.65%
10Y*
3.86%
ALL TIME*
-10.60%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$133.30M$134.04M$155.03M
$11.43M$14.01M$13.32M

RGLD vs. RIGL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
RGLD
Royal Gold, Inc.
-10.20%70.43%10.39%8.70%8.51%0.04%-12.13%44.27%5.53%31.32%
RIGL
Rigel Pharmaceuticals, Inc.
-14.06%154.64%16.00%-3.33%-43.40%-24.29%63.55%-6.96%-40.72%63.03%

Correlation

The correlation between RGLD and RIGL is 0.13, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.13

Correlation (3Y)
Balances recent behavior with more history.

0.15

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.12

Correlation (10Y)
Provides a long-term view across more market conditions.

0.10

Correlation (All Time)
Calculated using the full available price history since Nov 29, 2000

0.09

Fundamentals

Market Cap

RGLD:

$16.83B

RIGL:

$681.06M

EPS

RGLD:

$8.21

RIGL:

$18.94

PE Ratio

RGLD:

24.15

RIGL:

1.94

PEG Ratio

RGLD:

1.64

RIGL:

0.00

PS Ratio

RGLD:

11.72

RIGL:

2.36

PB Ratio

RGLD:

2.27

RIGL:

1.81

Total Revenue (TTM)

RGLD:

$1.31B

RIGL:

$299.77M

Gross Profit (TTM)

RGLD:

$579.68M

RIGL:

$279.95M

EBITDA (TTM)

RGLD:

$949.59M

RIGL:

$125.80M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RGLD vs. RIGL — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

RGLD
RGLD Risk / Return Rank: 6666
Overall Rank
RGLD Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
RGLD Sortino Ratio Rank: 6666
Sortino Ratio Rank
RGLD Omega Ratio Rank: 6565
Omega Ratio Rank
RGLD Calmar Ratio Rank: 6464
Calmar Ratio Rank
RGLD Martin Ratio Rank: 6464
Martin Ratio Rank

RIGL
RIGL Risk / Return Rank: 7575
Overall Rank
RIGL Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
RIGL Sortino Ratio Rank: 7979
Sortino Ratio Rank
RIGL Omega Ratio Rank: 7777
Omega Ratio Rank
RIGL Calmar Ratio Rank: 7474
Calmar Ratio Rank
RIGL Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

RGLD vs. RIGL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Royal Gold, Inc. (RGLD) and Rigel Pharmaceuticals, Inc. (RIGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RGLDRIGLDifference
Sharpe ratioReturn per unit of total volatility

-0.26

Sortino ratioReturn per unit of downside risk

-0.71

Omega ratioGain probability vs. loss probability

1.16

1.25

-0.09

Calmar ratioReturn relative to maximum drawdown

0.85

1.50

-0.66

Martin ratioReturn relative to average drawdown

1.84

2.51

-0.68

RGLD vs. RIGL - Sharpe Ratio Comparison

The current RGLD Sharpe Ratio is 0.81, which is comparable to the RIGL Sharpe Ratio of 1.07. The chart below compares the historical Sharpe Ratios of RGLD and RIGL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RGLD vs. RIGL - Drawdown Comparison

The maximum RGLD drawdown since its inception was -98.29%, roughly equal to the maximum RIGL drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for RGLD and RIGL.


Loading charts...

Drawdown Indicators


RGLDRIGLDifference

Max Drawdown

Largest peak-to-trough decline

-98.29%

-99.37%

+1.08%

Max Drawdown (1Y)

Largest decline over 1 year

-38.17%

-50.08%

+11.91%

Max Drawdown (3Y)

Largest decline over 3 years

-38.17%

-50.76%

+12.59%

Max Drawdown (5Y)

Largest decline over 5 years

-40.73%

-83.85%

+43.12%

Max Drawdown (10Y)

Largest decline over 10 years

-49.55%

-86.40%

+36.85%

Current Drawdown

Current decline from peak

-34.54%

-96.55%

+62.01%

Average Drawdown

Average peak-to-trough decline

-29.83%

-90.93%

+61.10%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.52%

29.86%

-12.34%

Volatility

RGLD vs. RIGL - Volatility Comparison

The current volatility for Royal Gold, Inc. (RGLD) is 9.95%, while Rigel Pharmaceuticals, Inc. (RIGL) has a volatility of 11.97%. This indicates that RGLD experiences smaller price fluctuations and is considered to be less risky than RIGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RGLDRIGLDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.95%

11.97%

-2.02%

Volatility (6M)

Calculated over the trailing 6-month period

31.80%

34.77%

-2.97%

Volatility (1Y)

Calculated over the trailing 1-year period

39.83%

70.02%

-30.19%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

31.81%

85.52%

-53.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.63%

82.76%

-49.13%

Dividends

RGLD vs. RIGL - Dividend Comparison

RGLD's dividend yield for the trailing twelve months is around 0.95%, while RIGL has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
RGLD
Royal Gold, Inc.
0.95%0.81%1.21%1.24%1.24%1.14%1.05%0.87%1.17%1.17%1.45%1.81%
RIGL
Rigel Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

RGLD vs. RIGL - Financials Comparison

This section allows you to compare key financial metrics between Royal Gold, Inc. and Rigel Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

RGLD vs. RIGL - Profitability Comparison

The chart below illustrates the profitability comparison between Royal Gold, Inc. and Rigel Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

RGLD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Royal Gold, Inc. reported a gross profit of 0.00 and revenue of 469.13M. Therefore, the gross margin over that period was 0.0%.

RIGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.

RGLD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Royal Gold, Inc. reported an operating income of 297.09M and revenue of 469.13M, resulting in an operating margin of 63.3%.

RIGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.

RGLD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Royal Gold, Inc. reported a net income of 281.13M and revenue of 469.13M, resulting in a net margin of 59.9%.

RIGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.


Frequently Asked Questions


RGLD and RIGL have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RIGL has higher volatility (11.97%) compared to RGLD (9.95%). In terms of maximum drawdown, RGLD dropped -98.29% vs RIGL's -99.37%.

RIGL currently has the higher Sharpe Ratio (1.07 vs 0.81), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RGLD and RIGL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer